Marker Therapeutics, Inc.

NasdaqCM:MRKR Stock Report

Market Cap: US$30.2m

Marker Therapeutics Future Growth

Future criteria checks 2/6

Marker Therapeutics's earnings are forecast to decline at 38.9% per annum while its annual revenue is expected to grow at 70.7% per year. EPS is expected to decline by 10.4% per annum.

Key information

-38.9%

Earnings growth rate

-10.4%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate70.7%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Nov 2024

Recent future growth updates

Recent updates

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Oct 04
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Marker Therapeutics awarded $2M FDA grant for leukemia candidate

Sep 13

Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01, revenue of $0.79M misses by $1.71M

Aug 11

Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Jun 17
Companies Like Marker Therapeutics (NASDAQ:MRKR) Could Be Quite Risky

Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Mar 04
Marker Therapeutics (NASDAQ:MRKR) Will Have To Spend Its Cash Wisely

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Nov 19
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Marker Therapeutics: Passing Through A Catalyst Desert

Oct 22

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Aug 17
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

May 04
Here's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn Situation

Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Feb 22
Do Insiders Own Lots Of Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)?

Marker shares rise as it completes construction of its cGMP manufacturing facility

Jan 13

FDA lifts partial hold on Marker Therapeutics's leukemia trial with cell therapy

Jan 05

Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Dec 29
Is Marker Therapeutics (NASDAQ:MRKR) In A Good Position To Deliver On Growth Plans?

Marker Therapeutics EPS misses by $0.02

Nov 09

Earnings and Revenue Growth Forecasts

NasdaqCM:MRKR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262-67N/AN/A1
12/31/20254-44N/AN/A1
12/31/20245-11N/AN/A1
9/30/20245-10-9-9N/A
6/30/20244-10-11-11N/A
3/31/20243-12-14-14N/A
12/31/20233-14-16-16N/A
9/30/20233-14-20-20N/A
6/30/20234-17-27-27N/A
3/31/20234-14-18-21N/A
12/31/20224-20-27-27N/A
9/30/20224-26-26-26N/A
6/30/20223-33-27-25N/A
3/31/20222-43-36-31N/A
12/31/20211-42-30-27N/A
9/30/2021N/A-41-35-28N/A
6/30/2021N/A-36-34-27N/A
3/31/20210-31-35-24N/A
12/31/20200-29-29-20N/A
9/30/20201-25-24-19N/A
6/30/20201-23-23-19N/A
3/31/20200-23-19-19N/A
12/31/20190-21-19-18N/A
9/30/2019N/A-152-20-20N/A
6/30/2019N/A-151-18-18N/A
3/31/20190-150-16-16N/A
12/31/20180-148-15-14N/A
9/30/20180-15-11-11N/A
6/30/20180-15N/A-9N/A
3/31/20180-12N/A-9N/A
12/31/20170-11N/A-8N/A
9/30/20170-10N/A-8N/A
6/30/2017N/A-8N/A-8N/A
3/31/2017N/A0N/A-8N/A
12/31/2016N/A-2N/A-7N/A
9/30/2016N/A-3N/A-6N/A
6/30/2016N/A28N/A-5N/A
3/31/2016N/A-38N/A-4N/A
12/31/2015N/A-34N/A-4N/A
9/30/2015N/A-33N/A-4N/A
6/30/2015N/A-63N/A-3N/A
3/31/2015N/A-2N/A-3N/A
12/31/2014N/A-31N/A-2N/A
9/30/2014N/A-34N/A-1N/A
6/30/2014N/A-33N/A-1N/A
3/31/2014N/A-35N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRKR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MRKR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MRKR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MRKR's revenue (70.7% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: MRKR's revenue (70.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MRKR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 23:40
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Marker Therapeutics, Inc. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Yun ZhongJanney Montgomery Scott LLC
Aydin HuseynovLadenburg Thalmann & Company